IRVINE, Calif.--(BUSINESS WIRE)--Pegasus Biologics, a privately held developer of unique bioimplants for soft tissue repair, and wound care for diabetic ulcers, announced today the appointment of Michael Will as Chief Executive Officer.
Keegan Harper, Chairman of the Pegasus Biologics’ Board announced, “Michael Will has a long and impressive background in the medical device industry and is a strong addition to the Pegasus Biologics’ organization. His years of experience and proven track record of growing medical device businesses, revenue creation, strategic leadership and team building abilities make him extremely qualified to carry Pegasus Biologics, Inc. to the next level.”
